Romidepsin
Niemann-Pick Disease, Type C
Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Niemann-Pick Disease, Type C cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
N-Acetyl-L-Leucine IntraBio Inc | Phase 3 | B |
2-HYDROXYPROPYL BETA-CYCLODEXTRIN (DS 4.2) Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company | Phase 2/3 | B |
Arimoclomol ZevraDenmark | Phase 2/3 | CCC |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
Fludarabine Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
View all 10 →
Same molecule, other indications
Romidepsin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →